PubMed Health⌕ Search

PubMed · 11890788

Quantum dot on a rope.

Abstract

The conjugation of nanoparticles (NPs) typically yields supramolecular materials which are fairly rigid, and the electronic coupling between the NP and other structural units of these compounds is fixed by covalent bonds. Here, we report on a novel bichromophor system constructed from a quantum dot tethered to a semiconducting polymer, which demonstrates the possibility of the dynamic interunit coupling in the NP supramolecules. The NP bichromophoric system was made on the basis of the layer-by-layer assembled (LBL) films of an anionic polyelectrolyte with poly(p-phenylene ethynylene) backbone, aPPE, and poly(allylamine hydrochloride) PAH polycation. To conjugate CdTe NPs to the (aPPE/PAH)(m) LBL film, we took advantage of the reactive groups of NP stabilizer, that is, -COOH, and the aminogroups on PAH. Tethering of CdTe was accomplished by using poly(ethyleneglycole), PEG, chains with two reactive terminals such as t-BOC-NH-PEG-COO-NHS. The evidence for successful conjugation of NPs to the LBL films can be seen both in AFM images and in optical data. The latter also indicate that the light quanta emitted by the NPs originate from the light absorption of the polymer film, which proves the presence of the aPPE-->NP energy-transfer process. The average separation distance between the NPs tethered to the LBL films can be changed by altering the dielectric properties of the solvent affecting PEG tether coiling (water/alcohol mixture). The reduced emission intensity of aPPE was found to follow the extension of the PEG tether. The quenching of aPPE is reversible when the original composition of the solvent mixture is restored. Thus, CdTe-PEG-aPPE is an example of an organized NP system with tunable optical coupling. Variable electronic coupling offers a convenient structural platform for new nanotechnological devices for which spatial control translates into a higher level of sophistication. PEG molecules afford a wide variety of polymer chain configurations with different reactive terminals, which makes possible the preparation of diverse NP superstructures.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sebastian Westenhoff, Nicholas A Kotov. 2002-03-20. Quantum dot on a rope.. https://doi.org/10.1021/ja0173728

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗